ABVC BioPharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ABVC Nasdaq 2830 www.abvcpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ABVC BioPharma, Inc.

ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology - Jun 26th, 2025 6:00 am
ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment - Jun 24th, 2025 6:00 am
ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million - Jun 6th, 2025 6:30 am
ABVC BioPharma Announces Board Approval of Share Dividend Showing Confidence in Subsidiary Growth and Long-Term Shareholder Value - Jun 3rd, 2025 4:00 am
ABVC BioPharma Regains Nasdaq Minimum Bid Price Compliance - May 14th, 2025 7:00 am
ABVC BioPharma Secures Japanese Patent for Its Natural MDD Treatment Candidate ABV-1504 - May 9th, 2025 7:00 am
ABVC BioPharma Announces First Quarter 2025 Financial Results and Strategic Planning for AI-Driven Agricultural Project in Taiwan - May 1st, 2025 6:30 am
UPDATE: ABVC BioPharma Announces 2024 Financial Results - Apr 16th, 2025 7:00 am
ABVC BioPharma Announces 2024 Financial Results - Apr 15th, 2025 2:30 pm
ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million - Apr 3rd, 2025 7:00 am
ABVC BioPharma Maintains Lucrative Global Licensing Agreements and Promising CDMO Acquisition, Strengthening Growth Potential - Mar 19th, 2025 7:00 am
ABVC BioPharma Plans to Expand Investment in U.S. for Production Facilities and Products for Unmet Medical Needs - Mar 5th, 2025 2:01 pm
ABVC and BioLite Japan Implement Strategy to Advance Japan's Biotech Innovation Into Global Markets - Feb 26th, 2025 2:01 pm
ABVC BioPharma Announces Potential $7M Cash Licensing Income from Existing Agreements in 2025 - Feb 20th, 2025 7:00 am
Positive Market Response in Asia Fuels Potential Revenue Growth for ABVC and BioKey, Marching Into Global Dietary Supplements Market of USD 75.35 Billion - Feb 12th, 2025 6:30 am
ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Jan 16th, 2025 6:30 am
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market - Jan 15th, 2025 6:30 am
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees - Jan 14th, 2025 6:30 am
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement - Jan 13th, 2025 7:00 am
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products - Jan 7th, 2025 6:30 am